The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Cardiff firm Hugh James has been instructed to act for the Seroxat Users Group on its lobbying of the Department of Health. The group wants an investigation into the increasing number of reported illnesses connected with the antidepressant drug Seroxat, produced by pharmaceutical giant GlaxoSmithKline. Partner Mark Harvey is leading the now 400-strong group. He won the instruction through a referral from niche health-related litigation firm Alexander Harris, which acts for the Prozac Users Group. Harvey has a reputation in this field, having acted on the Roaccutane and Minocycline cases as well as the anti-arthritis drug Opren, which resulted in a successful settlement. Not all of the group's participants are interested in taking action. Harvey said: "We're not saying the drug's bad; we're saying that not enough people have been warned of the potential symptoms." Some users found it difficult coming off the drug, but GlaxoSmithKline, which has yet to instruct lawyers, maintains that Seroxat is non-addictive.